Lab study tests a nose spray method to carry a chemo drug toward the brain
Original title: Design and Evaluation of PLGA-Based Hybrid Nanoparticles for Nasal Paclitaxel Delivery: Formulation Optimization, Barrier Transport, and Cytotoxicity Assessment.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done on cells in a lab, not in people. It is a very early step.
This was only tested on cells in a lab dish.
The short version
Scientists made tiny drug-filled particles meant to be sprayed in the nose, and tested them only in the lab.
What was studied. Researchers packed a chemo drug called paclitaxel into very tiny particles. They wanted a way to send the drug from the nose to the brain. They tested the particles on nose cells and on glioblastoma: A glioma that is given grade 4, the highest grade. It grows fast. Treatment usually starts soon after it is found. It often means surgery, then radiation and chemotherapy. See the glossary tumor cells grown in dishes.
What they found. The tiny particles helped more of the drug pass through a layer of nose cells than the drug alone. They did not harm the nose cell layer. In tumor cells in a dish, the particles killed more cells than taxol or temozolomide: A chemotherapy taken as a capsule, used for some brain tumors. Your team checks your blood counts while you are on it. See the glossary did.
What this means, and what it doesn't
What it could mean: Paclitaxel is a strong drug against brain tumors, but it has trouble reaching the brain. A nose spray could one day be a new way to get it there. This study is an early step toward testing that idea.
What it doesn't mean: This was only done with cells in a dish. It has not been tested in animals or in people yet. It is many years away from everyday care, if it ever gets there. It is not a cure, and it should not change anyone's treatment today.
Source: PubMed, August 30, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.